Phase 1Completed
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of GM-CT-01 in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors
- Sponsor
- Galectin Therapeutics Inc. (Industry)
- Enrollment
- 40 enrolled
- Conditions
- Colorectal Cancer; Lung Cancer; Breast Cancer; Head and Neck Cancer; Prostate Cancer
- Interventions
- GM-CT-01; 5-fluorouracil
- Ages
- adults, older adults
- Registry
- NCT00054977
Full record on ClinicalTrials.gov
From the registry
This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice. The primary reason for doing the study is to determine the safety of GM-CT-01 given alone and in combination with therapeutical dosage of 5-Fluorouracil, in patients who have advanced cancer that can be measured by CT scan.
Primary outcomes
- Safety
History
Last registry update
Study completion
Primary completion
Registered
Started